Paradigm Biopharmaceuticals Ltd. inanena kuti maphunziro oyamba adasinthidwa mwachisawawa ndikumwedwa ku United States (US) mu PARA_OA_002 pivotal Clinic trial, kuyesa injectable pentosan polysulfate sodium (PPS/Zilosul®) pofuna kuchiza ululu wokhudzana ndi mafupa a bondo (kOA). ). Phunziro loyamba la randomization linatsimikiziridwa ku Northwestern University, Chicago, ndi Wofufuza Wotsogolera, Dr. Thomas Schnitzer MD, Ph.D.
Kafukufuku wofunikira kwambiri padziko lonse lapansi Phase III, PARA_OA_002, pano akuwunika ndikulembetsa anthu m'magawo asanu ndi atatu ku Australia ndipo 21 mwa malo 56 osankhidwa mu US Clinical trial site activation akhala akuyang'ana kwambiri Paradigm kuyambira kumayambiriro kwa chaka cha kalendala kuti athe dziwe lalikulu la omwe atha kuzindikirika pamasamba omwe atsegulidwa ndikuyamba kuwunika. Kutsegula masamba ku US kupitilirabe, ndipo masamba aku UK ndi EU akuyambikanso mu CY22 yonse.
"Kukhala ndi maphunziro athu oyamba ku US ndichinthu chofunikira kwambiri pazachipatala cha OA. Gulu lachipatala la Paradigm lakhala likugwira ntchito molimbika kuti ayambitse ndi kuyambitsa masamba ku US, ndipo tikuwona anthu ambiri akulowa gawo lowunika ku US zomwe zachitika kwa omwe tili nawo," adatero Dr. Donna Skerrett, Chief Medical Officer wa Paradigm komanso CEO wa Interim.
ZOMWE MUNGACHITE PA NKHANIYI:
- Kafukufuku wofunikira kwambiri padziko lonse wa Phase III, PARA_OA_002, pano akuwunika ndikulembetsa anthu m'mawebusayiti asanu ndi atatu ku Australia ndi 21 mwa masamba 56 osankhidwa ku U.
- Kutsegulira kwa malo oyeserera kuchipatala kwakhala kofunikira kwambiri kwa Paradigm kuyambira koyambirira kwa chaka cha kalendala kuti athe dziwe lalikulu la omwe angathe kudziwika pamasamba omwe adatsegulidwa ndikuyamba kuwunika.
- Gulu lachipatala la Paradigm lakhala likugwira ntchito molimbika kuyambitsa ndi kuyambitsa masamba ku U.
